{"schema_version":"1.0","type":"article","title":"Anthropic's Drug Lab Will Sell to Pharma","url":"https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab-en.md","lang":"en","date":"2026-11-01","publish_at":"2026-11-01T08:00:00+08:00","updated_at":"2026-11-01","category":"商業分析系列","topic":"商業分析系列","tags":["Anthropic","AI drug discovery","IPO","Novo Nordisk","CDMO"],"summary":"Anthropic's S-1 shows $16.29bn in H1 2026 revenue and puts a wet lab, Coefficient Bio and in-house drug programs into its growth story. It is not running human trials, and nine of the top ten drugmakers are customers. Its likeliest path: license candidates to pharma.","key_points":["On October 28, Anthropic said it had bought Mithril Medicine, a one-person company whose founder used Claude to coordinate 11 outside labs and took a rare-muscle-disease antibody from idea to mouse data in under 18 months.","Anthropic's S-1, made public on October 26, 2026, shows first-half 2026 revenue of $16.29 billion and a $80.75 billion net loss, of which $72.39 billion was non-cash fair-value changes; the operating loss was $693 million.","As of September 30, 2026, nine of the ten largest drugmakers in the Fortune 500 were Anthropic customers; Novo Nordisk signed with OpenAI in April 2026 and with Anthropic in September 2026."],"facts":[{"claim":"Anthropic H1 2026 revenue","value":16286,"unit":"USD million","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"claim":"Anthropic H1 2025 revenue","value":1163,"unit":"USD million","as_of":"2025-06-30","source":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"claim":"Anthropic H1 2026 net loss","value":80748,"unit":"USD million","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"claim":"Anthropic H1 2026 fair-value loss on convertible notes, derivatives and SAFEs (non-cash)","value":72388,"unit":"USD million","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"claim":"Anthropic H1 2026 operating loss","value":693,"unit":"USD million","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"claim":"Anthropic H1 2025 operating loss","value":2135,"unit":"USD million","as_of":"2025-06-30","source":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"claim":"Anthropic Q2 2026 operating income","value":974,"unit":"USD million","as_of":"2026-06-30","source":"https://finance.yahoo.com/technology/live/anthropic-ipo-live-updates-frontier-ai-lab-discloses-revenue-and-risks-in-highly-anticipated-s-1-filing-141702607.html"},{"claim":"Anthropic S-1 public date and Nasdaq ticker","value":"2026-10-26 / ANT","unit":"","as_of":"2026-10-26","source":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"claim":"Top-10 Fortune 500 pharma companies that are Anthropic customers","value":9,"unit":"companies","as_of":"2026-09-30","source":"https://www.beckershospitalreview.com/healthcare-information-technology/ai/anthropic-ipo-filing-flags-healthcare-drug-discovery-as-growth-bets/"},{"claim":"Anthropic customers with ≥$100K trailing-12-month revenue","value":11900,"unit":"companies (more than)","as_of":"2026-09-30","source":"https://www.beckershospitalreview.com/healthcare-information-technology/ai/anthropic-ipo-filing-flags-healthcare-drug-discovery-as-growth-bets/"},{"claim":"Coefficient Bio purchase price (reported, stock)","value":400,"unit":"USD million","as_of":"2026-09-18","source":"https://ca.finance.yahoo.com/news/exclusive-anthropic-quietly-sets-biology-100255331.html"},{"claim":"Scientific skills, connectors and databases in Claude Science","value":60,"unit":"more than","as_of":"2026-07-08","source":"https://technews.tw/2026/07/08/anthropic-launches-claude-science-for-in-house-ai-drug-discovery/"},{"claim":"Claude agents used in the ART enzyme search","value":950,"unit":"about","as_of":"2026-09-23","source":"https://forklog.com/en/news/claude-ai-helps-uncover-new-enzyme-system-in-bacteriophage-dna"},{"claim":"Duration of the ART enzyme search","value":21,"unit":"hours","as_of":"2026-09-23","source":"https://forklog.com/en/news/claude-ai-helps-uncover-new-enzyme-system-in-bacteriophage-dna"},{"claim":"Reverse transcriptases screened in the ART search","value":200000,"unit":"more than","as_of":"2026-09-23","source":"https://forklog.com/en/news/claude-ai-helps-uncover-new-enzyme-system-in-bacteriophage-dna"},{"claim":"Narasimhan estimate of research-to-approval time with AI platforms","value":"7–8","unit":"years (from about 12)","as_of":"2026-07-08","source":"https://technews.tw/2026/07/08/anthropic-launches-claude-science-for-in-house-ai-drug-discovery/"},{"claim":"Narasimhan estimate of industry success rate with AI","value":16,"unit":"% (from about 8%)","as_of":"2026-07-08","source":"https://technews.tw/2026/07/08/anthropic-launches-claude-science-for-in-house-ai-drug-discovery/"},{"claim":"Novo Nordisk–Anthropic collaboration date","value":"2026-09-16","unit":"","as_of":"2026-09-16","source":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916768"},{"claim":"Novo Nordisk–OpenAI partnership date","value":"2026-04-14","unit":"","as_of":"2026-04-14","source":"https://www.fiercepharma.com/pharma/novo-taps-openai-deploy-ai-across-rd-manufacturing-and-corporate-functions"},{"claim":"OpenAI Orchestra Bio acquisition date","value":"2026-10-20","unit":"","as_of":"2026-10-20","source":"https://unite.ai/openai-acquires-orchestra-bio-to-expand-rosalind-life-sciences-tools"},{"claim":"Isomorphic Labs May 2026 funding","value":2100,"unit":"USD million","as_of":"2026-05-12","source":"https://whtc.com/2026/05/12/google-backed-isomorphic-raises-2-1-billion-to-scale-ai-driven-drug-discovery/"},{"claim":"Nextlink becomes Anthropic Taiwan distributor","value":"2026-01-23","unit":"","as_of":"2026-01-23","source":"https://wantrich.chinatimes.com/news/20260123900310-420101"},{"claim":"Anthropic compute spending commitment under the SpaceXAI Arrangements, through 2029","value":120500,"unit":"USD million (up to)","as_of":"2026-10-26","source":"https://finance.yahoo.com/technology/live/anthropic-ipo-live-updates-frontier-ai-lab-discloses-revenue-and-risks-in-highly-anticipated-s-1-filing-141702607.html"},{"claim":"Protein clusters covered in the ART enzyme search","value":1.9,"unit":"billion (about)","as_of":"2026-09-23","source":"https://forklog.com/en/news/claude-ai-helps-uncover-new-enzyme-system-in-bacteriophage-dna"},{"claim":"Insilico Medicine–Servier oncology deal value (up to), January 2026","value":888,"unit":"USD million","as_of":"2026-07-08","source":"https://technews.tw/2026/07/08/anthropic-launches-claude-science-for-in-house-ai-drug-discovery/"}],"sections":["01 | \"Not competing\" is only half true","02 | A one-person drug company, bought by Anthropic","03 | Only one of the two ledgers makes money","04 | Pharma's answer: sign with both","05 | Where Taiwan fits","06 | A seat at the table, not a pipeline","References"],"references":[{"title":"Anthropic, PBC Form S-1","source":"U.S. SEC","date":"2026-10-26","url":"https://www.sec.gov/Archives/edgar/data/0002130357/000162828026067168/anthropicpbc-sx1.htm"},{"title":"Exclusive: Anthropic quietly sets up biology lab as it ramps AI drug program","source":"Reuters (via Yahoo Finance","date":"2026-09-18","url":"https://ca.finance.yahoo.com/news/exclusive-anthropic-quietly-sets-biology-100255331.html"},{"title":"Anthropic IPO filing flags healthcare, drug discovery as growth bets","source":"Becker's Hospital Review","date":"2026-10-26","url":"https://www.beckershospitalreview.com/healthcare-information-technology/ai/anthropic-ipo-filing-flags-healthcare-drug-discovery-as-growth-bets/"},{"title":"Anthropic IPO live updates: S-1 filing discloses $16.3B in first-half revenue","source":"Yahoo Finance","date":"2026-10-26","url":"https://finance.yahoo.com/technology/live/anthropic-ipo-live-updates-frontier-ai-lab-discloses-revenue-and-risks-in-highly-anticipated-s-1-filing-141702607.html"},{"title":"What Anthropic's S-1 Reveals About Its Plans For Scientific Research","source":"Forbes","date":"2026-10-26","url":"https://www.forbes.com/sites/alexknapp/2026/10/26/anthropics-s-1-promises-new-scientific-discoveries-and-new-threats/"},{"title":"Anthropic launches Claude Science for in-house AI drug discovery","source":"TechNews","date":"2026-07-08","url":"https://technews.tw/2026/07/08/anthropic-launches-claude-science-for-in-house-ai-drug-discovery/"},{"title":"Claude AI helps uncover new enzyme system in bacteriophage DNA","source":"ForkLog","date":"2026-09-24","url":"https://forklog.com/en/news/claude-ai-helps-uncover-new-enzyme-system-in-bacteriophage-dna"},{"title":"Anthropic is operating a lab that conducts biology experiments","source":"TechCrunch","date":"2026-09-18","url":"https://techcrunch.com/2026/09/18/anthropic-is-operating-a-lab-that-conducts-biology-experiments/"},{"title":"Novo Nordisk and Anthropic collaborate on drug discovery","source":"Novo Nordisk","date":"2026-09-16","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916768"},{"title":"Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions","source":"Fierce Pharma","date":"2026-04-14","url":"https://www.fiercepharma.com/pharma/novo-taps-openai-deploy-ai-across-rd-manufacturing-and-corporate-functions"},{"title":"OpenAI acquires Orchestra Bio to expand Rosalind life sciences tools","source":"Unite.AI","date":"2026-10-20","url":"https://unite.ai/openai-acquires-orchestra-bio-to-expand-rosalind-life-sciences-tools"},{"title":"Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery","source":"Reuters (via WHTC","date":"2026-05-12","url":"https://whtc.com/2026/05/12/google-backed-isomorphic-raises-2-1-billion-to-scale-ai-driven-drug-discovery/"},{"title":"Nextlink Technology becomes Anthropic distribution partner in Taiwan","source":"Commercial Times","date":"2026-01-23","url":"https://wantrich.chinatimes.com/news/20260123900310-420101"},{"title":"EirGenix at BIO 2026: CDMO and biosimilar dual track","source":"GeneOnline","date":"2026-06-30","url":"https://geneonline.news/bio2026-eirgenix-026newsjune/"},{"title":"Anthropic buys a one-person biotech and starts its own drug programmes","source":"The Next Web","date":"2026-10-28","url":"https://thenextweb.com/news/anthropic-mithril-acquisition-claude-drug-development"}],"images":[{"alt":"Fig. 1 | Anthropic assembled a drug lab in six months","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-lab-en/figure-01.png"},{"alt":"Fig. 2 | Revenue up 14x; most of the loss is on paper","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-lab-en/figure-02.png"},{"alt":"Fig. 3 | Three ways AI companies approach drugs","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-lab-en/figure-03.png"},{"alt":"Fig. 4 | The model company stops at the candidate","url":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-lab-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anthropic-ipo-ai-drug-lab-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-01）。Anthropic's Drug Lab Will Sell to Pharma。https://drugnews.com.tw/articles/2026-11-01-anthropic-ipo-ai-drug-lab-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"fb_body":"Nine of the ten largest drugmakers use Claude. On October 26 its maker, Anthropic, filed an IPO prospectus that puts a wet lab, the reported ~$400 million stock acquisition of Coefficient Bio and in-house drug programs into its growth story.\n\nThe filing also answers pharma's worry. First-half revenue was $16.29 billion; $72.39 billion of the $80.75 billion net loss was non-cash, and the operating line turned positive in Q2. The money comes from selling models. Anthropic says it is not running human trials for now.\n\nBy the end of 2027, Anthropic's first in-house program will go to a drugmaker through a license or co-development deal. It wants a seat at pharma's licensing table, not pharma's patients.","relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}